+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Portal Hypertension- Pipeline Insights, 2019

  • ID: 4600447
  • Drug Pipelines
  • August 2018
  • Region: Global
  • DelveInsight
1 of 3


  • Adare Pharmaceuticals
  • Conatus Pharmaceuticals
  • Ferring Pharmaceuticals
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Mezzion Pharma
  • MORE
"Portal Hypertension- Pipeline Insights, 2019" report outlays comprehensive insights of present scenario and growth prospects across Portal Hypertension. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 3+ active products along with 3+ companies involved. Cumberland Pharmaceuticals and Conatus Pharmaceuticals are among the major drug developers as per the current pipeline scenario.

Products covered by Phase
  • Phase II
  • Unknown Stage
  • Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Portal Hypertension
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Portal Hypertension
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.


Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides an overview of therapeutic pipeline activity for Portal Hypertension across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Portal Hypertension therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Portal Hypertension
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Portal Hypertension to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Portal Hypertension R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Portal Hypertension to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Note: Product cover images may vary from those shown
2 of 3


  • Adare Pharmaceuticals
  • Conatus Pharmaceuticals
  • Ferring Pharmaceuticals
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Mezzion Pharma
  • MORE
Executive Summary

Disease Overview






Management and Treatment

Pipeline Therapeutics (Active Products)

Pipeline Therapeutics (Inactive Products)

Comparative Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Ifetroban: Cumberland Pharmaceuticals

Product Description

Research and Development

Product Development Activities

The list continues…..

Unknown Stage Products

Comparative Analysis

Therapeutic Assessment: Active Products

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Inactive Products

Comparative Analysis

Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Adare Pharmaceuticals
  • Conatus Pharmaceuticals
  • Cumberland Pharmaceuticals
  • Ferring Pharmaceuticals
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Mezzion Pharma
  • Novartis
  • ONO Pharmaceuticals
Note: Product cover images may vary from those shown